Razan Shahin

Discussing the value of the subsidiary OmniaBio, as soveriegn capacity that is critical to Canada's needs in the event of future pandemics or national emergency, leading to support from federal entitities that supply capital and other financial products. Continued effort to maintain strong support for strategic value of the Strategic Response Fund support for the project re the application of automation and AI technology in our recently opened cell and gene therapy manufacutring facility operated by the subsidiary OmniaBio. The support will result in lower cost of life saving cell and gene therapy products. Pursue opportunities to benefit the Canadian cell and gene therapy ecosystem caused by global uncertainty.

Engage National Defence, Health, and Global Affairs Canada on national readiness in response to emerging global health threats. Engage Health and National Defence concerning Emergent's Winnipeg facility for the production of medical countermeasures. To work with government to make NARCAN® (Naloxone HCI) Nasal Spray more widely available across Canada to facilitate immediate treatment to individuals suffering from opioid overdose. Seek funding support from the Strategic Innovation Fund to expand Emergent's Winnipeg facility. Discuss changes to take home naloxone program. Eligibility for Scientific Research and Experimental Development tax incentives. Engage government regarding the need for sustainable manufacturing, procurement and stockpiling of medical countermeasures used to diagnose, prevent, or treat diseases related to chemical, biological, radiological, or nuclear threats.

Engage government regarding the need for sustainable manufacturing, procurement and stockpiling of medical countermeasures used to diagnose, prevent, or treat diseases related to chemical, biological, radiological, or nuclear threats. Engage National Defence, Health, and Global Affairs Canada on national readiness in response to emerging global health threats. To work with government to make NARCAN® (Naloxone HCI) Nasal Spray more widely available across Canada to facilitate immediate treatment to individuals suffering from opioid overdose. Eligibility for Scientific Research and Experimental Development tax incentives. Discuss changes to take home naloxone program. Engage Health and National Defence concerning Emergent's Winnipeg facility for the production of medical countermeasures. Seek funding support from the Strategic Innovation Fund to expand Emergent's Winnipeg facility.

Voyageur Pharmaceuticals would like to engage with the Government of Canada to explore federal programs, grants, and investment incentives that would support the company's continued operations and growth in Alberta. Discussion may include opportunities to enhance the competitiveness of the company's Canadian footprint and to identify federal measures that would help retain jobs, innovation capacity, and long-term investment in Canada.

Communications regarding funding from various Government funding programs, opportunities to improve government activity (funding, tax incentives, clinical trials infrastructure, etc) to encourage the innovation economy in Canada with a specific focus on biotech, and programs around procurement opportunities for the Government of Canada relating to biotechnology products.

Support the establishment of a life sciences strategy in Canada Advocate in support of a pan-Canadian school food program. Advocate for the implementation of a federal diabetes and obesity strategy. Advocate for the establishment of public-private partnerships to support chronic disease prevention.